Danaher (NYSE:DHR – Get Free Report) had its target price cut by equities research analysts at Raymond James from $250.00 to $240.00 in a report released on Wednesday, Benzinga reports. The firm currently has an “outperform” rating on the conglomerate’s stock. Raymond James’ price objective points to a potential upside of 23.91% from the company’s previous close.
DHR has been the topic of a number of other research reports. Stifel Nicolaus decreased their target price on shares of Danaher from $250.00 to $240.00 and set a “hold” rating on the stock in a research report on Wednesday, July 26th. Wells Fargo & Company decreased their target price on shares of Danaher from $285.00 to $247.00 and set an “overweight” rating on the stock in a research report on Tuesday, October 3rd. Royal Bank of Canada lifted their target price on shares of Danaher from $260.00 to $292.00 in a research report on Wednesday, July 26th. KeyCorp decreased their price objective on shares of Danaher from $325.00 to $300.00 and set an “overweight” rating on the stock in a research report on Wednesday, September 27th. Finally, Barclays boosted their price objective on shares of Danaher from $260.00 to $290.00 and gave the company an “overweight” rating in a research report on Tuesday, July 25th. Three equities research analysts have rated the stock with a hold rating and fifteen have assigned a buy rating to the company. Based on data from MarketBeat.com, Danaher currently has a consensus rating of “Moderate Buy” and a consensus target price of $257.73.
Check Out Our Latest Research Report on DHR
Danaher Stock Performance
Danaher (NYSE:DHR – Get Free Report) last issued its earnings results on Tuesday, October 24th. The conglomerate reported $2.02 EPS for the quarter, topping analysts’ consensus estimates of $1.83 by $0.19. The company had revenue of $6.87 billion for the quarter, compared to analysts’ expectations of $6.60 billion. Danaher had a net margin of 20.01% and a return on equity of 13.87%. The firm’s revenue was down 10.3% compared to the same quarter last year. During the same quarter last year, the company earned $2.56 EPS. As a group, equities research analysts predict that Danaher will post 8.58 EPS for the current fiscal year.
Insider Buying and Selling
In related news, SVP Jose-Carlos Gutierrez-Ramos sold 590 shares of the business’s stock in a transaction dated Monday, August 21st. The shares were sold at an average price of $250.54, for a total transaction of $147,818.60. Following the sale, the senior vice president now owns 6,939 shares of the company’s stock, valued at $1,738,497.06. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. 11.10% of the stock is currently owned by insiders.
Institutional Investors Weigh In On Danaher
Several hedge funds have recently bought and sold shares of DHR. GPS Wealth Strategies Group LLC bought a new stake in Danaher during the first quarter worth about $25,000. DHJJ Financial Advisors Ltd. bought a new position in shares of Danaher in the third quarter worth approximately $25,000. Silicon Valley Capital Partners bought a new position in shares of Danaher in the first quarter worth approximately $29,000. IAG Wealth Partners LLC lifted its stake in shares of Danaher by 344.8% in the second quarter. IAG Wealth Partners LLC now owns 129 shares of the conglomerate’s stock worth $31,000 after buying an additional 100 shares in the last quarter. Finally, Stone House Investment Management LLC bought a new position in shares of Danaher in the first quarter worth approximately $32,000. Institutional investors own 76.71% of the company’s stock.
Danaher Company Profile
Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes and services; and healthcare filtration solutions.
Read More
- Five stocks we like better than Danaher
- What is Put Option Volume?
- Watch for bears as S&P 500 slices 200-day line
- Airline Stocks – Top Airline Stocks to Buy Now
- Reasons UPS is a strong sell: Reasons to buy it when it bottoms
- 3 Tickers Leading a Meme Stock Revival
- 3 hot mid-caps set to report Q3 earnings
Receive News & Ratings for Danaher Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Danaher and related companies with MarketBeat.com's FREE daily email newsletter.
